Imatinib mesylate effectively combines with chaperone-rich cell lysate loaded dendritic cells to treat bcr-abl+ murine leukemia.

被引：0
|
作者：
Zeng, Y [1 ]
Graner, MW [1 ]
Feng, HP [1 ]
Li, G [1 ]
Katsanis, E [1 ]
机构：
[1] Univ Arizona, Tucson, AZ 85721 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5011
引用
收藏
页码：322B / 322B
页数：1
相关论文
共 15 条
  • [1] Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia
    Zeng, Y
    Graner, MW
    Feng, HP
    Li, G
    Katsanis, E
    INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (02) : 251 - 259
  • [2] Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells
    Zeng, Y
    Graner, MW
    Thompson, S
    Marron, M
    Katsanis, E
    BLOOD, 2005, 105 (05) : 2016 - 2022
  • [3] Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia
    Kislin, Kerri L.
    Marron, Marilyn T.
    Li, Gang
    Graner, Michael W.
    Katsanis, Emmanuel
    FASEB JOURNAL, 2007, 21 (09): : 2173 - 2184
  • [4] Tumor-derived chaperone-rich cell lysate (CRCL) can be effectively combined with syngeneic bone marrow transplantation to treat Bcr-abil leukemia in a murine model.
    Chen, XC
    Zeng, Y
    Li, G
    Thompson, S
    Sepassi, M
    Romanoski, MA
    Graner, MW
    Katsanis, E
    BLOOD, 2004, 104 (11) : 811A - 811A
  • [5] Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells
    Palama, Ilaria E.
    Leporatti, Stefano
    de Luca, Emanuela
    Di Renzo, Nicola
    Maffia, Michele
    Gambacorti-Passerini, Carlo
    Rinaldi, Ross
    Gigli, Giuseppe
    Cingolani, Roberto
    Coluccia, Addolorata M. L.
    NANOMEDICINE, 2010, 5 (03) : 419 - 431
  • [6] Leukemia-derived chaperone-rich cell lysates (CRCL) provide bcr-abl specific immunity.
    Zeng, Y
    Graner, MW
    Feng, HP
    Katsanis, E
    BLOOD, 2003, 102 (11) : 655A - 655A
  • [7] Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity
    Zeng, Y
    Feng, HP
    Graner, MW
    Katsanis, E
    BLOOD, 2003, 101 (11) : 4485 - 4491
  • [8] Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation
    Boissel, Nicolas
    Rousselot, Philippe
    Raffoux, Emmanuel
    Cayuela, Jean-Michel
    Soulier, Jean
    Mooney, Nuala
    Charron, Dominique
    Dombret, Herve
    Toubert, Antoine
    Rea, Delphine
    JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (04) : 747 - 756
  • [9] Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia
    Janikashvili, Nona
    LaCasse, Collin J.
    Larmonier, Claire
    Trad, Malika
    Herrell, Amanda
    Bustamante, Sara
    Bonnotte, Bernard
    Har-Noy, Michael
    Larmonier, Nicolas
    Katsanis, Emmanuel
    BLOOD, 2011, 117 (05) : 1555 - 1564
  • [10] Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice
    Bu, Ning
    Wu, Haiqin
    Zhang, Guilian
    Zhan, Shuqin
    Zhang, Ru
    Sun, Hong
    Du, Yun
    Yao, Li
    Wang, Huqing
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2015, 56 (03) : 631 - 643
12